GLP-1 receptor agonists are intended for adults with obesity (BMI 30) or those who are overweight (BMI 27) with associated metabolic conditions such as hypertension, dyslipidaemia, or type 2 diabetes
However, limited data are available regarding the kidney effects of GLP-1 RA in real-world settings [18], especially regarding albuminuria-based outcomes or eGFR slopes
They are not intended for human or animal consumption, injection, ingestion, topical use, self-experimentation, performance enhancement, or therapeutic use
Participants were excluded if they had significant medical histories, abnormal lab results, or conditions affecting alcohol metabolism or absorption of the investigational product
Certain supplement ingredients, such as L-carnitine tartrate and Panax ginseng , have been shown to increase the expression of androgen receptors